Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other ...

ALX Oncology (ALXO) announced “encouraging” data from an ongoing Phase 1/2 investigator-sponsored trial of the company’s lead clinical ...

Just over a month after laying off staff to focus on its lead cancer candidate, ALX Oncology announced that the asset ...

(RTTNews) - ALX Oncology Holdings Inc. (ALXO),announced Friday that its Phase 2 ASPEN-03 and ASPEN-04 trials evaluating evorpacept in combination with Merck's KEYTRUDA or pembrolizumab in advanced ...

Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R2) was well-tolerated and ...

ALX Oncology (ALXO) announced topline data from its Phase 2 ASPEN-03 and ASPEN-04 clinical trials. The company’s investigational CD47-blocker evorpacept, when added to Merck’s (MRK ...

Data to be presented at AACR 2025 Annual Meeting suggest the combination of ALX Oncology’s investigational CD47-blocker, evorpacept, plus rituximab and lenalidomide (R 2) was well-tolerated and ...

In advanced head and neck squamous cell carcinoma, evorpacept and Keytruda didn’t meet the primary endpoints of the ASPEN-03 ...

About Evorpacept ALX Oncology's lead therapeutic candidate, evorpacept, is a highly differentiated potential best- and first-in-class CD47 checkpoint inhibitor and one of the most advanced ...

ALX On­col­o­gy’s ef­forts to progress a CD47 com­bo hit a ma­jor speed bump. The com­pa­ny said Fri­day that two tri­als test­ing … ...